Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indacaterol/mometasone - Novartis

Next Previous
Drug Profile

Indacaterol/mometasone - Novartis

Alternative Names: Atectura; Atectura Breezhaler; IND/MF; Mometasone furoate/indacaterol acetate; Mometasone/indacaterol; QMF Twisthaler®; QMF-149

Latest Information Update: 30 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Merck & Co; Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Glucocorticoids; Indans; Pregnadienediols; Quinolones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Jan 2026 Indacaterol/​Mometasone is still in phase III trials for in Asthma (In children, Adjunctive treatment) in South Africa (Inhalation) (NCT05562466)
  • 30 Jan 2026 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Europe, Australia, Israel, Hong Kong, Malaysia, Singapore, South Africa, Czech Republic, Thailand, Slovakia, Spain (Inhalation)
  • 30 Jan 2026 Discontinued - Phase-III for Chronic obstructive pulmonary disease (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top